Skeletal Muscle Cell Biology

Natural products targeting secondary pathological mechanisms in Duchenne muscular dystrophy: a scoping review

Sihombing, Maic Audo Eybi Mayer, Kim, Min Seok, Kim, Young Sook
Springer Nature · 2026-11-18 · DOI 10.1186/s13395-026-00461-2

Abstract

Background Duchenne muscular dystrophy (DMD) is caused by dystrophin deficiency and is accompanied by interconnected secondary pathological processes, including chronic inflammation, oxidative stress, impaired muscle regeneration, fibrosis, mitochondrial dysfunction, calcium dysregulation, and vascular dysfunction. Natural products have been investigated as experimental modulators of several of these processes, but the evidence is heterogeneous in intervention type, model, exposure, and outcome. Methods A systematic search of PubMed, Scopus, Web of Science, ScienceDirect, and Cochrane Library (2015–2024) identified studies evaluating natural products (NPs) in DMD models. Data were analyzed focusing on the molecular mechanisms of action and pharmacological outcomes. Results Twenty-one primary studies met the DMD-specific criteria after two non-DMD-model reports were excluded from the initially charted 23 records. The eligible evidence was predominantly preclinical, with one small clinical pilot that included a DMD subgroup. Based on reconciled outcome charting, inflammation (12/21), oxidative stress (8/21), regeneration (12/21), fibrosis (10/21), and mitochondrial-related processes (4/21) were represented; these overlapping counts require final primary-paper verification. Direct compounds, complex formulations, delivery adjuncts, and ex vivo cell-expansion reagents were considered separately. Conclusions The literature maps natural-product interventions to multiple secondary mechanisms relevant to DMD, but it remains predominantly preclinical and methodologically heterogeneous. The current evidence does not establish DMD-specific clinical efficacy, long-term safety, corticosteroid-sparing effects, or a role in standard care. Future work should use prospectively defined DMD models and outcomes, transparent pharmacokinetic and safety reporting, and adequately powered DMD-specific clinical studies. ∙ Twenty-one studies met the DMD-specific eligibility criteria after exclusion of two non-DMD-model reports from the original 23-study chart. ∙ Based on the revised descriptive mapping (n=21), 12 studies reported inflammation-related endpoints, eight oxidative-stress endpoints, 12 regeneration-related endpoints, 10 fibrosis-related endpoints, and four mitochondrial-related endpoints; all require final primary-source verification. ∙ The evidence spans direct compounds, multi-component formulations, and enabling adjuncts, which should not be interpreted as a single intervention class. ∙ Eighteen eligible studies included mdx-background mice; other evidence came from sapje zebrafish, DMD-derived cardiomyocytes, or a mixed-dystrophy clinical pilot. ∙ The available evidence supports mechanistic mapping but not clinical efficacy, safety, corticosteroid-sparing effects, or integration into standard care.

Read at publisher →